XML 31 R20.htm IDEA: XBRL DOCUMENT v3.25.3
Revenues
 9 Months Ended
Sep. 30, 2025
Revenue from Contract with Customer [Abstract]  
Revenues Revenues
The following table presents a summary of total revenues (in thousands): 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
Xywav$431,410 $388,466 $1,191,535 $1,072,238 
Xyrem35,663 58,114 108,253 184,526 
Epidiolex/Epidyolex302,608 251,558 772,075 697,376 
Sativex4,752 4,586 14,774 13,704 
Total Neuroscience774,433 702,724 2,086,637 1,967,844 
Rylaze/Enrylaze99,868 98,780 294,760 309,359 
Zepzelca79,295 85,843 216,869 241,990 
Defitelio/defibrotide 51,752 65,818 140,520 158,915 
Vyxeos37,583 34,313 111,978 109,348 
Ziihera8,306 — 16,272 — 
Modeyso11,032 — 11,502 — 
Total Oncology287,836 284,754 791,901 819,612 
Other2,143 2,229 10,863 8,497 
Product sales, net1,064,412 989,707 2,889,401 2,795,953 
High-sodium oxybate AG royalty revenue52,945 58,157 156,029 162,268 
Other royalty and contract revenues8,750 7,105 24,230 22,556 
Total revenues$1,126,107 $1,054,969 $3,069,660 $2,980,777 
The following table presents a summary of total revenues attributed to geographic sources (in thousands): 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
United States$1,020,476 $953,669 $2,755,273 $2,686,486 
Europe86,405 77,318 252,206 230,821 
All other19,226 23,982 62,181 63,470 
Total revenues$1,126,107 $1,054,969 $3,069,660 $2,980,777 
The following table presents a summary of the percentage of total revenues from customers that represented more than 10% of our total revenues: 
Three Months Ended
September 30,		Nine Months Ended
September 30,
2025202420252024
ESSDS41 %42 %42 %42 %
ASD11 %10 %11 %9 %
McKesson11 %13 %11 %12 %
Financing and payment
Our payment terms vary by the type and location of our customer but payment is generally required in a term ranging from 30 to 65 days.